✦ LIBER ✦

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Four Doses of Tasosartan in Patients With Essential Hypertension

✍ Scribed by Yves Lacourcière; James L. Pool; Laura Svetkey; Alan H. Gradman; Pierre Larochelle; Jacques de Champlain; William B. Smith

Book ID: 117602936
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 242 KB
Volume: 11
Category: Article
ISSN: 0895-7061
DOI: 10.1016/s0895-7061(97)00487-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension

✍ Raymond R. Townsend; Christopher B. McFadden; Virginia Ford; Jenny A. Cadée 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 94 KB

Treatment of separation anxiety in dogs

Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial

✍ J.N. King; B.S. Simpson; K.L. Overall; D. Appleby; P. Pageat; C. Ross; J.P. Chau 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Multicenter, double-blind clinical trial

Multicenter, double-blind clinical trial with different doses of pinacidil in patients with mild-to-moderate essential hypertension

✍ Giuseppe Licata; Attilio Ganguzza; Ferruccio Galletti; Fabrizio Poeta; Enrico Bo 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 693 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

The PEARL-HF (Multicenter, Randomized, D

The PEARL-HF (Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose to Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial

✍ Bertram Pitt; I.-Zu Huang; Stefan Anker; David Bushinsky; Dalane Kitzman; Faiez 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 95 KB

A randomized, multicenter, double-blind,

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis

✍ Robert Bissonnette; Kim Papp; Yves Poulin; Gilles Lauzon; Launa Aspeslet; Robert 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 167 KB